UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, ~~D.C.~~DC 20549

FORM 8-K

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(d) OF THE

~~SECURITIES~~ ~~EXCHANGE ACT OF 1934~~

Date of report (Date of earliest event reported): ~~June~~August 231, 2025

IRADIMED CORPORATION

(Exact ~~Name~~name of ~~Registrant~~registrant as ~~Specified~~specified in ~~Its~~its ~~Charter~~charter)

Delaware

(State or ~~Other~~other ~~Jurisdiction~~jurisdiction of ~~Incorporation~~incorporation)


001-36534		73-1408526
(Commission File Number)		(IRS Employer Identification No.)

1025 Willa Springs Dr., Winter Springs, FL		32708
12705 Ingenuity Drive, Orlando, Florida		32826
(Address of Principal Executive Offices)		(Zip Code)
(Address of principal executive offices)		(Zip Code)

(407) 677-8022

(Registrant’s ~~Telephone~~telephone ~~Number~~number, ~~Including~~including ~~Area~~area ~~Code~~code)

(Former ~~Name~~name or ~~Former~~former ~~Address~~address, if ~~Changed~~changed ~~Since~~since ~~Last~~last ~~Report~~report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ~~(see General Instruction A.2. below)~~:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class:		Trading Symbol		Name of each exchange on which registered:
Common stock, par value $0.0001		IRMD		NASDAQ ~~Capital~~Global Market

Item 2.02Results of Operations and Financial Condition.

On August 1, 2025, IRADIMED CORPORATION issued a press release (the “Press Release”) announcing its financial results for the quarter ended June 30, 2025. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that Section. Furthermore, such information, including Exhibit 99.1, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01Financial Statements and Exhibits.

(d) Exhibits


Exhibit No.	Description

99.1	Press release dated August 1, 2025.

104	Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)

Item 5.07Submission of Matters to a Vote of Security Holders.

The Annual Meeting of Stockholders of Iradimed Corporation (“Iradimed”) was held on Thursday, June 19, 2025. At the meeting, Iradimed’s stockholders voted on the following three proposals and cast their votes as described below.

1. Stockholders elected each of Roger Susi, Monty Allen, Anthony Vuoto, Hilda Scharen-Guivel and James Hawkins to Iradimed’s Board of Directors, each to hold office until a succeeding annual meeting of stockholders or until such director’s successor shall have been duly elected and qualified (or, if earlier, such director’s removal or resignation from our Board), as set forth below.

Name	Votes For	Votes Withheld	Broker Non-Votes
Roger Susi	8,851,894	2,226,129	709,490
Monty Allen	9,535,898	1,542,125	709,490
Anthony Vuoto	10,760,158	317,865	709,490
Hilda Scharen-Guivel	10,799,780	278,243	709,490
James Hawkins	8,376,696	2,701,327	709,490

2. Stockholders ratified the selection of RSM US LLP as Iradimed’s independent registered public accounting firm to perform independent audit services for the fiscal year ending December 31, 2025, as set forth below.

11,617,62
Votes For	Votes Against	Abstentions
11,775,729	10,385	1,399

3. Stockholders approved an advisory resolution on the compensation of Iradimed’s named executive officers.

Votes For	Votes Against	Abstentions	Broker Non-Votes
10,777,171	286,889	13,963	709,490

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	IRADIMED CORPORATION

Date: June 23, 2025
Date: August 1, 2025

	By:	/s/John Glenn
	Name:	John Glenn
	Title:	Chief Financial Officer

Filing Compare · IRADIMED CORP